Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)

  • Technology appraisal
  • TA1058
  • Published: 

History

Documents created during the development process.

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6162